Pharmaceuticals Australia

Australia Amyloidosis Treatment Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Australia Amyloidosis Treatment Market Industry Trends and Forecast to 2034: Segmented by (Type, Drug Class, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $104.8 Mn Placeholder estimate
Estimate 2025 $120.9 Mn 1.3% of the global market
Projected 2034 $438.9 Mn 263% Adds $318.0 Mn over 9 forecast years
CAGR 2025–2034 15.4% Faster than 74% of 180 Pharmaceuticals markets here
Key players 5
  • Australia is 1.33% of the global market.
  • In APAC, the largest is China at $787.3 Mn.
  • Fastest growing: India at 17% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$318.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Amyloidosis Treatment Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $104.8 Mn — —
2025 (base) $120.9 Mn +$16.1 Mn —
2026 (forecast) $139.5 Mn +$18.6 Mn +15.4%
2027 (forecast) $161.0 Mn +$21.5 Mn +33.2%
2028 (forecast) $185.8 Mn +$24.8 Mn +53.7%
2029 (forecast) $214.4 Mn +$28.6 Mn +77.3%
2030 (forecast) $247.5 Mn +$33.0 Mn +104.7%
2031 (forecast) $285.6 Mn +$38.1 Mn +136.2%
2032 (forecast) $329.6 Mn +$44.0 Mn +172.5%
2033 (forecast) $380.3 Mn +$50.8 Mn +214.5%
2034 (forecast) $438.9 Mn +$58.6 Mn +263%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Amyloidosis Treatment Market Analysis at a glance
Market size, 2025$120.9 Mn placeholder estimate
Forecast, 2034$438.9 Mn placeholder estimate
Growth (CAGR), 2025–203415.4% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsType, drug class and end user (see all)
Key playersPfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma, AstraZeneca (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials24 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Amyloidosis Treatment Market Analysis Executive Summary

Amyloidosis treatments stop or slow the build-up of abnormal proteins that damage the heart and nerves.

Key segments of the amyloidosis Treatment market include type (ATTR Amyloidosis and AL Amyloidosis) and drug class (TTR Stabilizers, TTR Silencers and Chemotherapy and Antibodies).

Bar chart: Australia Amyloidosis Treatment market size, 2024–2034, placeholder estimates. $104.8 Mn in 2024, $120.9 Mn in 2025 and $438.9 Mn in 2034, 15.4% CAGR.
Australia Amyloidosis Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Amyloidosis Treatment Market Dynamics

Market Growth Drivers

Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the amyloidosis Treatment market. More countries now have national rare disease plans.

Opportunity

Newborn genome screening, gene therapies and access programmes in emerging markets give the amyloidosis Treatment market strong growth.

Market Restraints

Very small patient numbers, long diagnosis delays, high treatment prices and limited specialist centres hold back the amyloidosis Treatment market.

Competitive Landscape for Amyloidosis Treatment Market in Australia

The amyloidosis Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Amyloidosis Treatment Market in Australia

Amyloidosis Treatment in Australia: rules, payment and research

Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 24 studies on Amyloidosis Treatment that are recruiting, active or about to start in Australia.⁠[3]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for amyloidosis Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Amyloidosis Treatment right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Amyloidosis Treatment in context

Australia compared

  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[1]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 18.1% of people (2025). World: 10.4% of people (2025). 3rd highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Amyloidosis Treatment market in Australia?
Placeholder estimate: about $120.9 Mn in 2025, rising to about $438.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Amyloidosis Treatment market in Australia growing?
Placeholder estimate: about 15.4% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Amyloidosis Treatment market report cover?
The report splits the market by type (ATTR Amyloidosis, AL Amyloidosis), drug class (TTR Stabilizers, TTR Silencers, Chemotherapy and Antibodies) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Amyloidosis Treatment market?
Key players include Pfizer Inc., Alnylam Pharmaceuticals, Ionis Pharmaceuticals, BridgeBio Pharma and AstraZeneca.
What is driving the Amyloidosis Treatment market?
Better genetic diagnosis, orphan drug incentives, patient advocacy and new gene and enzyme therapies are driving the amyloidosis Treatment market. More countries now have national rare disease plans.
Who regulates Amyloidosis Treatment in Australia?
Medicines must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Amyloidosis Treatment are running in Australia?
24 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
How much research is published on Amyloidosis Treatment?
PubMed lists 33 papers on Amyloidosis Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Australia

See all

Related on rare diseases and cardiovascular

See the topic